Search Our Online Directory

Featured Articles
  • New Pfizer Breast Cancer Drug is Achieving its ExpectationsThe world’s second-largest drug-maker, Pfizer, stated that, on Monday, the mid-stage study of their new experimental drug for palbociclin, or ...
  • Breast Pain Lumps and Cysts​Breast Cancer is a scary disease affecting women across the world. Lucky for us, this particular type of cancer is very curable if it is caught ...
  • Breast Cancer Statistics​Unfortunately, it is estimated that there will be 226,870 new cases of invasive breast cancer among ...
  • Breast Anatomy​The human female breast consists mainly of fat and breast tissue, along with the various nerves, veins, arteries and connective tissue that hold ...
  • Breasts and Men​Because men’s bodies were never designed to be able to breastfeed infants, men do not share the same complex breast growth and development that ...

Pfizer Grants Early Approval for Breast Cancer Drug

Pfizer Inc., the world’s second largest drugmaker via revenue, announced that the FDA will allow them to apply early for approval for their new breast cancer drug, based on the results of the drug’s mid-stage patient testing in the drug study PALOMA-1.

Basically, this means that Pfizer will, most likely, not be required to conduct even bigger and highly expensive late-stage patient testing studies that could delay Pfizer’s application at least a couple of years. This delay would force patients and doctors to wait even longer for the new drug, which, ultimately, reduces the gross amount of money the drug could bring in for Pfizer before its limited 20 year patent expires.

Essentially, the drug in question is palbociclib, combined with a drug called Femara (or letrozole). It is intended to be used for treatment of postmenopausal women with a specific form of highly developed breast cancer. Research thus far has shown that, by combining these two drugs, palbociclib and letrozole, patients, on average, were able to survive 20.2 months before the tumors worsened. This is about twice as long as the patients who receive only letrozole. 

Researchers have high hopes for the efficiency and success of the drug. Currently, if all goes according to desired plan, palbociclib will launch in 2015 with sales surpassing $1.9 billion by 2020. This drug is looking so optimistic, in fact, that, the day this early approval possibility was announced, Pfizers shares jumped up 1.7% and were up 15 cents at $29.21 by the time mid-afternoon trading occurred. 

Sources: ABC News

Related Articles
  • Whats a Mammogram A majority of young, and old, women around the world do not get their mammograms consistently enough to effectively prevent breast ...
  • Breasts and Men​Because men’s bodies were never designed to be able to breastfeed infants, men do not share the same complex breast growth and development that ...
  • ATLAS Tamoxifen Study A new study shows that the tried and true breast cancer drug tamoxifen is more effective when used for 10 years instead of the currently ...